ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3024% above fair value
$1443.50+16.22 (+1.14%)
Close on Nov 13, 2026Market cap $1.36TP/E 46.9Yield 0.43%
Eli Lilly r&d expenses
Research and development expenses are spending on new products and technology.
Eli Lilly's R&D Expenses for the twelve months ending Sep 30, 2026 was $15.38B, up 22.4% year over year. For fiscal 2025 it was $13.34B, up 21.3% from the year before. Over ten years it grew 10.8% a year on average. The highest annual figure on record is $13.34B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.34B | +21.3% |
| FY2024 | Dec 31, 2024 | $10.99B | +18.0% |
| FY2023 | Dec 31, 2023 | $9.31B | +29.5% |
| FY2022 | Dec 31, 2022 | $7.19B | +3.8% |
| FY2021 | Dec 31, 2021 | $6.93B | +16.0% |
| FY2020 | Dec 31, 2020 | $5.98B | +6.8% |
| FY2019 | Dec 31, 2019 | $5.60B | +10.8% |
| FY2018 | Dec 31, 2018 | $5.05B | -0.9% |
| FY2017 | Dec 31, 2017 | $5.10B | -4.0% |
| FY2016 | Dec 31, 2016 | $5.31B | +10.7% |
| FY2015 | Dec 31, 2015 | $4.80B | +1.3% |
| FY2014 | Dec 31, 2014 | $4.73B | -14.4% |
| FY2013 | Dec 31, 2013 | $5.53B | +4.8% |
| FY2012 | Dec 31, 2012 | $5.28B | +5.1% |
| FY2011 | Dec 31, 2011 | $5.02B | +2.8% |
| FY2010 | Dec 31, 2010 | $4.88B | +12.9% |
| FY2009 | Dec 31, 2009 | $4.33B | +12.6% |
| FY2008 | Dec 31, 2008 | $3.84B | +10.2% |
| FY2007 | Dec 31, 2007 | $3.49B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.25B | +22.5% |
| Q2 FY2026 | Jun 30, 2026 | $3.82B | +14.5% |
| Q1 FY2026 | Mar 31, 2026 | $3.51B | +28.4% |
| Q4 FY2025 | Dec 31, 2025 | $3.80B | +25.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.47B | +26.8% |
| Q2 FY2025 | Jun 30, 2025 | $3.34B | +23.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.73B | +8.4% |
| Q4 FY2024 | Dec 31, 2024 | $3.02B | +18.0% |
| Q3 FY2024 | Sep 30, 2024 | $2.73B | +13.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.71B | +15.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.52B | +27.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.56B | +28.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.41B | +33.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.36B | +32.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.99B | +23.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.00B | +5.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.80B | +5.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.78B | +7.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.61B | -3.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.90B | +9.8% |
| Q3 FY2021 | Sep 30, 2021 | $1.71B | +16.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.66B | +19.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.67B | +20.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.73B | +9.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.47B | +6.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.39B | -0.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.39B | +13.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.58B | +13.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.38B | +7.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.40B | +10.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.23B | +11.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.39B | +13.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.28B | -4.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.27B | -0.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.11B | -12.0% |
| Q4 FY2017 | Dec 31, 2017 | $1.23B | -19.2% |
| Q3 FY2017 | Sep 30, 2017 | $1.34B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.27B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.26B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.52B | – |
See a number that looks wrong?